Targeting MRSA's virulence pathways through nanocarrier systems offers a paradigm shift beyond traditional antibiotics. The next decade will require not only optimization and mechanistic validation but also innovative material design, scalable manufacturing, and integration into clinical practice to realize the promise of nanocarrier-enabled anti-MRSA therapies.
Ismail et al. (Tue,) studied this question.